Susceptibility to SARS-CoV-2 omicron following ChAdOx1 nCoV-19 and BNT162b2 versus CoronaVac vaccination
The emergence of SARS-CoV-2 variants raises concerns of reduced COVID-19 vaccine efficacy. We investigated the humoral immunity in uninfected and previously infected ChAdOx1 nCoV-19, BNT162b2 and CoronaVac vaccinees, who have received complete regimes of vaccines by means of a SARS-CoV-2 surrogate v...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Published: |
Cell Press
2022
|
| _version_ | 1825938840110497792 |
|---|---|
| author | Chua, Jia Xin Durrant, Lindy Gillian Chok, Yin Ling Lai, Oi Ming |
| author_facet | Chua, Jia Xin Durrant, Lindy Gillian Chok, Yin Ling Lai, Oi Ming |
| author_sort | Chua, Jia Xin |
| collection | UPM |
| description | The emergence of SARS-CoV-2 variants raises concerns of reduced COVID-19 vaccine efficacy. We investigated the humoral immunity in uninfected and previously infected ChAdOx1 nCoV-19, BNT162b2 and CoronaVac vaccinees, who have received complete regimes of vaccines by means of a SARS-CoV-2 surrogate virus blocking test. The ChAdOx1 nCoV-19 (p = 0.0013) and BNT162b2 (p = 0.0005) vaccines induced significant higher blocking activity with longer durability against the Spike (S) protein receptor binding domain (RBD) of wild type SARS-CoV-2 than the CoronaVac vaccine in uninfected vaccinees. Prior infection improved protection in the CoronaVac vaccinees. Subsequent investigation on the breadth of SARS-CoV-2 vaccine-induced antibody blocking responses, revealed that all vaccine platforms cross-protected uninfected vaccinees against all variant of concerns, except Omicron. Prior infection protected the ChAdOx1 nCoV-19 and BNT162b2 vaccinees against Omicron but not CoronaVac vaccinees. Our study suggests that vaccines that induce broader sterilizing immunity are essential to fight against fast-emerging variants. |
| first_indexed | 2024-03-06T11:18:18Z |
| format | Article |
| id | upm.eprints-103373 |
| institution | Universiti Putra Malaysia |
| last_indexed | 2024-03-06T11:18:18Z |
| publishDate | 2022 |
| publisher | Cell Press |
| record_format | dspace |
| spelling | upm.eprints-1033732023-06-14T02:54:24Z http://psasir.upm.edu.my/id/eprint/103373/ Susceptibility to SARS-CoV-2 omicron following ChAdOx1 nCoV-19 and BNT162b2 versus CoronaVac vaccination Chua, Jia Xin Durrant, Lindy Gillian Chok, Yin Ling Lai, Oi Ming The emergence of SARS-CoV-2 variants raises concerns of reduced COVID-19 vaccine efficacy. We investigated the humoral immunity in uninfected and previously infected ChAdOx1 nCoV-19, BNT162b2 and CoronaVac vaccinees, who have received complete regimes of vaccines by means of a SARS-CoV-2 surrogate virus blocking test. The ChAdOx1 nCoV-19 (p = 0.0013) and BNT162b2 (p = 0.0005) vaccines induced significant higher blocking activity with longer durability against the Spike (S) protein receptor binding domain (RBD) of wild type SARS-CoV-2 than the CoronaVac vaccine in uninfected vaccinees. Prior infection improved protection in the CoronaVac vaccinees. Subsequent investigation on the breadth of SARS-CoV-2 vaccine-induced antibody blocking responses, revealed that all vaccine platforms cross-protected uninfected vaccinees against all variant of concerns, except Omicron. Prior infection protected the ChAdOx1 nCoV-19 and BNT162b2 vaccinees against Omicron but not CoronaVac vaccinees. Our study suggests that vaccines that induce broader sterilizing immunity are essential to fight against fast-emerging variants. Cell Press 2022 Article PeerReviewed Chua, Jia Xin and Durrant, Lindy Gillian and Chok, Yin Ling and Lai, Oi Ming (2022) Susceptibility to SARS-CoV-2 omicron following ChAdOx1 nCoV-19 and BNT162b2 versus CoronaVac vaccination. iScience, 25 (11). art. no. 105379. pp. 1-24. ISSN 2589-0042 https://www.sciencedirect.com/science/article/pii/S2589004222016510 10.1016/j.isci.2022.105379 |
| spellingShingle | Chua, Jia Xin Durrant, Lindy Gillian Chok, Yin Ling Lai, Oi Ming Susceptibility to SARS-CoV-2 omicron following ChAdOx1 nCoV-19 and BNT162b2 versus CoronaVac vaccination |
| title | Susceptibility to SARS-CoV-2 omicron following ChAdOx1 nCoV-19 and BNT162b2 versus CoronaVac vaccination |
| title_full | Susceptibility to SARS-CoV-2 omicron following ChAdOx1 nCoV-19 and BNT162b2 versus CoronaVac vaccination |
| title_fullStr | Susceptibility to SARS-CoV-2 omicron following ChAdOx1 nCoV-19 and BNT162b2 versus CoronaVac vaccination |
| title_full_unstemmed | Susceptibility to SARS-CoV-2 omicron following ChAdOx1 nCoV-19 and BNT162b2 versus CoronaVac vaccination |
| title_short | Susceptibility to SARS-CoV-2 omicron following ChAdOx1 nCoV-19 and BNT162b2 versus CoronaVac vaccination |
| title_sort | susceptibility to sars cov 2 omicron following chadox1 ncov 19 and bnt162b2 versus coronavac vaccination |
| work_keys_str_mv | AT chuajiaxin susceptibilitytosarscov2omicronfollowingchadox1ncov19andbnt162b2versuscoronavacvaccination AT durrantlindygillian susceptibilitytosarscov2omicronfollowingchadox1ncov19andbnt162b2versuscoronavacvaccination AT chokyinling susceptibilitytosarscov2omicronfollowingchadox1ncov19andbnt162b2versuscoronavacvaccination AT laioiming susceptibilitytosarscov2omicronfollowingchadox1ncov19andbnt162b2versuscoronavacvaccination |